Skip to main content

Table 1 Summary of patients with endophthalmitis following intravitreal injection of anti-VEGF agent

From: Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms

Patient Diagnosis Medication Pre-injection VA VA at presentation Days to presentation Treatment Culture results Continued anti-VEGF? Final VA Length of follow-up (months)
1 BRVO/CME Bevacizumab 20/50 CF 2 Tap/inject CONS N 20/40 − 1 12
2 BRVO/CME Bevacizumab 20/100 HM 3 Tap/inject, then PPV CONS Y 20/125 23
3 CRVO/CME Bevacizumab 20/40 CF 15 PPV CONS N HM 26
4 DME Bevacizumab 20/60 CF 4 Tap/inject CONS Y 20/80 22
5 NVAMD Bevacizumab 20/40 − 2 20/80 3 Tap/inject CONS Y 20/80 25
6 Radiation retinopathy s/p plaque therapy for MM Ranibizumab 20/200 HM 3 Tap/inject CONS Y 20/250 11
7 NVAMD Ranibizumab 20/100 CF 7 Tap/inject, then PPV CONS N 20/160, ph 20/125 13
8 DME Bevacizumab ? (elsewhere) HM 4 Tap/inject, then PPV CONS Y 20/40 10
9 CRVO/CME Ranibizumab 20/63 CF 3 Tap/inject Corynebacterium Y 20/80 23
10 MC/CNV Ranibizumab 20/25 HM 1 Tap/inject, then PPV Strep viridans, Neisseria Y 20/160 16
11 NVAMD Bevacizumab ? (elsewhere) 20/400 4 Tap/inject, then PPV E. coli, Enterobacter cloacae N 20/50 + 2 4
12 NVAMD Bevacizumab 20/126 20/100 4 Tap/inject, then PPV Lactococcus garvieae, CONS Y 20/40 18
13 NVAMD Bevacizumab 20/80 CF 5 Tap/inject No growth Y 20/150 22
14 CRVO/CME Bevacizumab 20/250 − 3 HM 4 Tap/inject No growth N HM 4
15 NVAMD Ranibizumab 20/200 − 2 1/200 4 Tap/inject No growth N CF 21
16 CRVO/CME Ranibizumab ? 20/100 3 Tap/inject No growth Y ? 1
  1. Summary of patients with endophthalmitis following intravitreal injection of anti-VEGF agent
  2. Abbreviations: VA visual acuity, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, CME cystoid macular edema, DME diabetic macular edema, NVAMD neovascular age-related macular degeneration, MC multifocal choroiditis, CNV choroidal neovascularization, MM malignant choroidal melanoma, CF counting fingers, HM hand motions, PPV pars plana vitrectomy, CONS coagulase-negative Staphylococcus